Search
meglumine antimoniate (Glucantime in France, Glucantim in Italy)
Indications:
- cutaneous leishmaniasis
Dosage:
- parenteral (intravenous [2,3], intramuscular [1]
- 20 mg/kg/day for 20 days [5]
Adverse effects:
- fever, rash, arthralgia, abdominal pain
- skin eruption
- pruritus and erythema in the site of injection
- urticaria
- pancreatic toxicity: hyperamylasemia, increased serum lipase
- increased serum transaminases
- pancytopenia
- renal failure, hepatic failure, death
Notes:
- lower efficacy in treating cutaneous leishmaniasis in children than adults [5]
General
antiprotozoal agent
References
- Wikipedia: Meglumine antimoniate
http://en.wikipedia.org/wiki/Meglumine_antimoniate
- Mayo Clinic
Meglumine Antimoniate (Intravenous Route, Injection Route).
http://www.mayoclinic.org/drugs-supplements/meglumine-antimoniate-intravenous-route-injection-route/description/drg-20064644
- Ezzine Sebai N1, Mrabet N, Khaled A et al
[Side effects of meglumine antimoniate in cutaneous leishmaniasis:
15 cases].
Tunis Med. 2010 Jan;88(1):9-11.
PMID: 20415206
- Roberts WL et al
Characterization of the Antimonial Antileishmanial Agent
Meglumine Antimonate (Glucantime).
Antimicrob Agents Chemother. May 1998; 42(5): 1076-1082.
PMID: 9593130
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC105748/
- Layegh P, Rahsepar S, Rahsepar AA.
Systemic meglumine antimoniate in acute cutaneous leishmaniasis:
children versus adults.
Am J Trop Med Hyg. 2011 Apr;84(4):539-42. doi: 10.4269/ajtmh.2011.10-0002.
PMID: 21460006